T2 Biosystems reports preliminary Q4 revenue $2.3M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2025
0mins
Business Progress and Sales Growth: T2 Biosystems reported significant advancements in 2024, including an increase in the global installed base of T2Dx Instruments and record sales for their sepsis test panels, particularly in the U.S. and internationally.
Product Pipeline and Future Outlook: The company received FDA clearances for expanded testing capabilities and has three products designated as Breakthrough Devices, positioning them for accelerated sales and operational enhancements in 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
